Sabby Management, LLC Kazia Therapeutics LTD Transaction History

Sabby Management, LLC

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q1 2018 May 15, 2018	SELL	$2.88 - $6.25 $1.06 Million - $2.29 Million	-366,668 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$2.4 - $3.41 $880,003 - $1.25 Million	366,668	366,668 $0

2.13M

93.2K

Ticker KZIA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,111,300
Market Cap $47M
Description
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. It is also developing EVT801, an investigational new drug for various...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.